All News

Breast cancer threatens to silence the voices of those touched by it but if we choose to speak out, we will be heard.

The Food and Drug Administration (FDA) expedited the approval of Adcetris (brentuximab vedotin) in combination with chemotherapy for certain patients with peripheral T-cell lymphoma (PTCL).

We all have our cracks, and cancer provides a huge one. Perhaps for the first time ever, we present (and look) weak, vulnerable, sick and needing to ask others for help.

Young patients diagnosed with posterior uveal melanoma may have similar, if not worse, prognoses compared with the overall patient population.

Patients with BRAF wild-type advanced melanoma saw a survival benefit after treatment with Opdivo (nivolumab) compared with the chemotherapy agent dacarbazine.

The Food and Drug Administration (FDA) granted a breakthrough therapy designation to Adcetris (brentuximab vedotin) for the frontline treatment of certain lymphoma subtypes, according to Seattle Genetics, the manufacturer of the antibody-drug conjugate.

Scientists, physicians and patients collaborate to improve treatment for rare cancer.

Two women discuss their experience in cancer caregiving, while giving advice to others.

The combination use of two immunotherapy agents in the first-line setting helped patients with advanced melanoma live longer compared with treatment with either drug alone.

What can science tell us about life, death and disease?

We've got a sneak peek at what’s inside our Fall 2018 issue.

Cancer is costly. What if I did not have health insurance or a steady paycheck? Would I have fallen through the cracks and died of metastatic breast cancer before anybody told me I was sick? An exercise in role-playing taught me that there is help available.

Checkpoint inhibitors are moving into the treatment realm of renal cell carcinoma; however, questions still remain.

Being a patient advocate comes in many forms, and not all of them require you to get out of bed to storm the halls of Washington.

We all survived another October and the tidal wave of pink that represents breast cancer.

Preventing febrile neutropenia is crucial because the body’s white blood cells help to fight infection.

Giving thanks for cancer is a choice, and a difficult one at that. How can one give thanks for something so painful and traumatizing?

Lawrence D. Kaplan, M.D., discusses recent updates and next steps to be taken in Hodgkin, mantle cell and follicular lymphoma.

APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION ANNOUNCES NEW EXECUTIVE DIRECTOR

The Food and Drug Administration granted a priority review to Tecentriq (atezolizumab) plus Abraxane (nab-paclitaxel) for the frontline treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in patients whose disease expresses the PD-L1 protein, as determined by PD-L1 biomarker testing, according to Roche, the drug’s manufacturer.

Entospletinib monotherapy yielded limited activity in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma.

Given their proximity to both patients and information, lung cancer advocacy groups are in a good position to help better educate patients and physicians about the benefits of biomarker testing.

Imbruvica (ibrutinib) is a safe treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL), according to a pooled analysis of four clinical trials.

Making predictions on how cancer will affect your life from diagnosis to post treatment is a waste of time. No one knows what tomorrow will bring.

Lock Up Lung Cancer is a new campaign to expose the disease as a prolific killer, according to LUNG FORCE.

The FDA has granted a priority review designation to a supplemental new drug application (sNDA) for Lynparza (olaparib) tablets for use as a maintenance therapy in patients with newly-diagnosed, BRCA-positive advanced ovarian cancer who achieved a complete or partial response to standard frontline platinum-based chemotherapy.

At a local event, Shannon Pulaski – author of Mom’s Genes – shared her journey after being diagnosed with the BRCA mutation.

As an avid writer about my testicular cancer experiences, I'm sharing my writing process.

During this holiday season, one CURE contributor hopes that others will consider tissue or organ donation.

A panel of caregivers drew upon personal experience to offer advice and ideas to those in this role.